Targeting HER2 or EGFR Exon 20 Insertion Mutation in Lung Cancer - A Case Series from India

被引：0
|
作者：
Varughese, V. J. [1 ]
Joseph, S. [1 ]
Sirohi, B. [1 ]
Raut, N. [1 ]
Mathew, A. [1 ]
机构：
[1] Mosc Med Coll, Oncol, Kolenchery, Ernakulam, India
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
EGFR HER2 Exon 20 mutation; poziotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P50.08
引用
收藏
页码：S1117 / S1117
页数：1
相关论文
共 50 条
  • [41] Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non-Small-Cell Lung Cancer
    Tan, Aaron C.
    Saw, Stephanie P. L.
    Chen, Jianbin
    Lai, Gillianne G. Y.
    Nwe, Hlaing
    Takano, Angela
    Lau, Dawn P. X.
    Yeong, Joe P. S.
    Tan, Gek San
    Lim, Kiat Hon
    Skanderup, Anders J.
    Chan, Johan W. K.
    Teh, Yi Lin
    Rajasekaran, Tanujaa
    Jain, Amit
    Tan, Wan Ling
    Ng, Quan Sing
    Kanesvaran, Ravindran
    Lim, Wan-Teck
    Ang, Mei-Kim
    Tan, Daniel S. W.
    [J]. JCO PRECISION ONCOLOGY, 2022, 6
  • [42] Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
    Pacini, Laura
    Jenks, Andrew D.
    Vyse, Simon
    Wilding, Christopher P.
    Arthur, Amani
    Huang, Paul H.
    [J]. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2021, 14 : 301 - 317
  • [43] A case of non-small cell lung cancer with EGFR exon 20 insertion treated with osimertinib
    Morton-Gittens, Jamie
    Pipalia, Nisarg
    Liu, Hongxiang
    Thippu Jayaprakash, Kamalram
    [J]. LUNG CANCER, 2021, 156 : S73 - S74
  • [44] A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)
    Heymach, J.
    Negrao, M.
    Robichaux, J.
    Carter, B.
    Patel, A.
    Altan, M.
    Gibbons, D.
    Fossella, F.
    Simon, G.
    Lam, V.
    Blumenschein, G.
    Tsao, A.
    Kurie, J.
    Mott, F.
    Jenkins, D.
    Mack, D.
    Feng, L.
    Roeck, B.
    Yang, Z.
    Papadimitrakopoulou, V.
    Elamin, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S323 - S324
  • [45] Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer: Single-Institution Experience
    Lee, So Heun
    Jeong, Hyehyun
    Kim, Deok Hoon
    Jang, Se Jin
    Kim, Sang-We
    Yoon, Shinkyo
    Lee, Dae Ho
    [J]. CANCER RESEARCH AND TREATMENT, 2024, 56 (03): : 774 - 784
  • [46] Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
    Chen, Xuesong
    Zha, Wangjian
    Su, Mei
    Meng, Nan
    Cao, Shuliang
    Niu, Beifang
    Qi, Xu
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [47] Author Correction: EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
    Alex Friedlaender
    Vivek Subbiah
    Alessandro Russo
    Giuseppe Luigi Banna
    Umberto Malapelle
    Christian Rolfo
    Alfredo Addeo
    [J]. Nature Reviews Clinical Oncology, 2022, 19 : 70 - 70
  • [48] Advances in the Diagnosis and Treatment of Advanced Non-Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
    Liu, Jingwen
    Xiang, Yan
    Fang, Tingwen
    Zeng, Lulin
    Sun, Ao
    Lin, Yixiang
    Lu, Kaihua
    [J]. CLINICAL LUNG CANCER, 2024, 25 (02) : 100 - 108
  • [49] The impact of EGFR Exon 20 mutation subtypes on lung cancer prognosis.
    Xu, Ming
    Li, Yingmei
    Liu, Danni
    Mu, Tianhao
    Cheng, Nitao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] EGFR and HER2 mutation and gene amplification in non-small-cell lung cancer
    Toshihiko, Yokoyama
    Kondo, Masashi
    Goto, Yasuhiro
    Fukui, Takayuki
    Yoshioka, Hiromu
    Yokoi, Kohei
    Kondo, Yutaka
    Osada, Hirotaka
    Imaizumi, Kazuyoshi
    Hasegawa, Yoshinori
    Shimokata, Kaoru
    Sekido, Yoshitaka
    [J]. CANCER RESEARCH, 2006, 66 (08)
12345